Financials data is unavailable for this security.
View more
Year on year Arcus Biosciences Inc had net income fall 14.98% from a loss of 267.00m to a larger loss of 307.00m despite a 4.46% increase in revenues from 112.00m to 117.00m. An increase in the selling, general and administrative costs as a percentage of sales from 92.86% to 100.00% was a component in the falling net income despite rising revenues.
Gross margin | -- |
---|---|
Net profit margin | -100.81% |
Operating margin | -118.62% |
Return on assets | -20.70% |
---|---|
Return on equity | -41.47% |
Return on investment | -24.57% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Arcus Biosciences Inc fell by 79.00m. However, Cash Flow from Investing totalled 194.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 306.00m for operations while cash generated from financing totalled 33.00m.
Cash flow per share | -2.93 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 6.96 |
---|---|
Tangible book value per share | 6.96 |
More ▼
Balance sheet in USDView more
Current ratio | 5.14 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼